Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals.

@article{Kim2005RosiglitazoneRG,
  title={Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals.},
  author={Sun Hyung Kim and Fahim A. Abbasi and James W. Chu and Tracey L McLaughlin and Cindy Lamendola and Kenneth S. Polonsky and Gerald Mark Reaven},
  journal={Diabetes},
  year={2005},
  volume={54 8},
  pages={2447-52}
}
Compensatory hyperinsulinemia permitting insulin-resistant individuals to maintain normal glucose tolerance is associated with a left shift in the glucose-stimulated insulin secretion rate (GS-ISR) dose-response curve and decrease in the insulin metabolic clearance rate (I-MCR). To see whether these changes would reverse with improvement in insulin sensitivity, 14 nondiabetic insulin-resistant subjects received rosiglitazone for 12 weeks (4 mg daily for 4 weeks and then 8 mg daily for 8 weeks… CONTINUE READING